Pharma glass inner surface treatment innovation

Pharma glass inner surface treatment innovation

In line with its pharma approach and to better serve client needs, Stoelzle Pharma – Health and Safety has broadened its pharma primary packaging portfolio from type III soda-lime glass to type II glass containers with a surface inner treatment for higher hydrolytic resistance for acidic and neutral aqueous parenteral or non-parenteral preparations.

Via this technical breakthrough, Stoelzle aims to overcome such disadvantages as imprecise dosing or handling with toxic components and difficulties encountered with smaller size containers.

After extensive research, laboratory analysis and inline sample testing in the past year, Stoelzle reports to have developed a process with good stability over a wide range of filling volumes from 6ml to 250ml and adherence to all requirements of US and European Pharmacopoeias for type II glass.

The main components of the innovative liquid treatment process for Stoelzle type II glass are exclusively non-harmful substances: Air, water and ammonium sulphate.

Potentially harmful SO2/SO3 is only formed in minute quantities directly in the bottles and the used water further improves the hydrolytic resistance.

In accordance with Stoelzle´s environmental and social standards, which have been recognised with the Ecovadis gold rating, focus was placed on minimising the environmental impact through optimal dosing of ammonium sulphate adjusted to each bottle size, leading to raw material savings.

Series production of Stoelzle type II flint injection and infusion bottles of 6ml to 250ml volume is set to start in June 2021 at the Köflach plant Austria.

The site has two furnaces with a daily capacity of some 270 tons of glass. Currently, approximately 1.5 billion pieces of clear, amber and green glass packaging are produced annually on 11 fully automated production lines.

www.stoelzle.com

Published: 
10/12/2020

Hot Topics